Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
EDISON EQUITY RESEARCH: BAVARIAN NORDIC – ADR OUTLOOK The BMS and J&J deals, and continued Imvamune related income have provided Bavarian Nordic with validation of its vaccine...
Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments;...
EDISON EQUITY RESEARCH: BAVARIAN NORDIC - STRATEGIC EBOLDA DEAL FILLS 2015 REVENUE GAP Bavarian Nordic’s $187m exclusive global licensing and supply deal for its development Ebola vaccine...
KVISTGAARD, Denmark, July 24, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of...
KVISTGAARD, Denmark, May 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Paul Chaplin, Ph.D. has been appointed new President and CEO of the Company...
KVISTGAARD, Denmark, May 15, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today two papers featuring the combination of the Company's proprietary cancer...
KVISTGAARD, Denmark, May 14, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first quarter of 2014. Revenue...
KVISTGAARD, Denmark, April 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now been treated in a randomized, prospective Phase 2...
KVISTGAARD, Denmark, March 19, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK...
Alliance For Biosecurity Elects Chief Executive Officers Of Bavarian Nordic And Elusys Therapeutics As New Co-Chairs Leadership Team Will Advance Industry Efforts Supporting the Development of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.94 | -10.4560622914 | 8.99 | 9.32 | 7.76 | 15139 | 8.3759214 | DR |
| 4 | -1.03 | -11.3436123348 | 9.08 | 9.42 | 7.76 | 9027 | 8.74197911 | DR |
| 12 | -1.35 | -14.3617021277 | 9.4 | 9.64 | 7.76 | 18734 | 8.81722508 | DR |
| 26 | -0.62 | -7.15109573241 | 8.67 | 15.11 | 7.76 | 57795 | 12.07116077 | DR |
| 52 | 0.69 | 9.375 | 7.36 | 15.11 | 6.86 | 32300 | 11.76144425 | DR |
| 156 | -1.42 | -14.994720169 | 9.47 | 20.67 | 5.85 | 46826 | 13.21239841 | DR |
| 260 | -4.2 | -34.2857142857 | 12.25 | 20.67 | 5.04 | 37862 | 13.21020279 | DR |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
